Insmed Stock Jumps 16%: Revenue Surges 268% as Brinsupri Crosses $1 Billion

Insmed stock jumped about 16% on Thursday, October 29, 2026, after the biotech company reported third-quarter revenue of $524.4 million — up 268% from a year earlier — driven by its lung therapy Brinsupri, which has now passed $1 billion in sales in its first four full quarters on the market. The shares traded near $113 as investors focused on the revenue beat and raised guidance, even though the company still posted a net loss.

What happened

Insmed reported total revenue of $524.4 million for the quarter ended September 30, 2026, compared with $142.3 million in the same quarter last year. That beat the consensus estimate of roughly $501 million. Brinsupri (brensocatib), a once-daily oral therapy for non-cystic fibrosis bronchiectasis, generated $400.1 million in the quarter — up 29% from the second quarter. Arikayce, Insmed's inhaled therapy for Mycobacterium avium complex lung disease, added $124.4 million, up 9% year over year.

The bottom line is still negative, but it is moving sharply in the right direction. Insmed posted a net loss of $100.3 million, or $0.46 per share, compared with a loss of $370.0 million, or $1.75 per share, a year earlier. The per-share loss was wider than the roughly $0.34 to $0.38 loss analysts had modeled, yet the market largely looked past it. Operating loss narrowed to $89.4 million from $366.0 million a year ago, and the company held about $1.1 billion in cash, cash equivalents and marketable securities at September 30.

Why it is blowing up

First, the scale of the Brinsupri launch is rare. A single new therapy passing $1 billion within its first four full quarters puts it in blockbuster territory unusually fast, and the 29% sequential growth in the quarter suggests demand is still accelerating rather than flattening after launch. Second, management raised guidance instead of merely repeating it. Insmed lifted its full-year 2026 Brinsupri revenue outlook to $1.35 billion to $1.40 billion, from $1.25 billion to $1.40 billion previously, and raised Arikayce guidance to $460 million to $470 million, from $450 million to $470 million.

Third, the growth story is going international and deeper into the pipeline. Insmed launched Brinsupri in Japan in October 2026 after approval there as the country's first approved therapy for this condition, in a market the company says includes about 150,000 diagnosed bronchiectasis patients. In the United States, the Food and Drug Administration granted priority review to a supplemental application for Arikayce, with a target action date of January 28, 2027, and the company said the agency does not currently plan an advisory committee meeting. Management also reiterated long-term peak revenue expectations of more than $7 billion for Brinsupri and more than $6 billion for its investigational TPIP program, and said the company is transitioning toward cash-flow positivity in 2027.

Key facts

Revenue: $524.4 million in Q3 2026, up 268% from $142.3 million a year earlier, beating consensus near $501 million.
Brinsupri: $400.1 million in the quarter, up 29% sequentially; more than $1 billion in its first four full quarters.
Arikayce: $124.4 million, up 9% year over year.
Net loss: $100.3 million, or $0.46 per share, narrowed from $370.0 million, or $1.75 per share, a year earlier.
Guidance raised: Brinsupri to $1.35–$1.40 billion for 2026; Arikayce to $460–$470 million.
Cash: about $1.1 billion at September 30, 2026.
Stock reaction: shares rose about 16% on Thursday, trading near $113.

What is next

The next checkpoints are concrete. Investors will watch whether Brinsupri's sequential growth holds after the Japan launch, whether the January 28, 2027 FDA decision expands Arikayce's label in the United States, and whether the promised move toward cash-flow positivity in 2027 stays on track as research and selling costs rise — research and development spending rose about 45% in the quarter. The loss per share missing estimates is the main caution in the report: revenue is scaling fast, but profitability is not here yet. For now, the market's verdict on Thursday was clear — a 268% revenue surge and a guidance raise outweighed a wider-than-expected loss. This report describes what happened and why markets reacted; it is not a recommendation to buy, sell or hold any security.

Sources

FAQ

Why did Insmed stock jump on October 29, 2026?

Insmed reported Q3 revenue of $524.4 million, up 268% year over year and above consensus near $501 million, and raised full-year guidance for both Brinsupri and Arikayce. Shares rose about 16% despite a wider-than-expected per-share loss.

What is Brinsupri and how much did it sell?

Brinsupri (brensocatib) is Insmed's once-daily oral therapy for non-cystic fibrosis bronchiectasis. It generated $400.1 million in Q3 2026, up 29% from the prior quarter, and has passed $1 billion in its first four full quarters.

Is Insmed profitable yet?

No. Insmed posted a net loss of $100.3 million, or $0.46 per share, in Q3 2026 — much narrower than the $370.0 million loss a year earlier — and management said it is transitioning toward cash-flow positivity in 2027.

What did Insmed guide for 2026?

The company raised Brinsupri's 2026 revenue guidance to $1.35–$1.40 billion and Arikayce's to $460–$470 million, citing U.S. commercial momentum and international growth.